Dahinden C A, Geiser T, Brunner T, von Tscharner V, Caput D, Ferrara P, Minty A, Baggiolini M
Institute of Clinical Immunology, University Hospital Bern, Switzerland.
J Exp Med. 1994 Feb 1;179(2):751-6. doi: 10.1084/jem.179.2.751.
CC chemokines constitute a novel class of cytokines that attract and activate monocytes and lymphocytes, as well as basophil and eosinophil leukocytes, with distinct target cell profiles, and are believed to be involved in the regulation of different types of inflammation. The action of the recently identified monocyte chemotactic protein 3 (MCP-3) on human basophil and eosinophil function was studied and compared with that of other CC chemokines. In basophils, MCP-3, MCP-1, RANTES, and macrophage inflammatory protein (MIP)-1 alpha all induced cytosolic-free calcium concentration ([Ca2+]i) changes and, with different efficacies, chemotaxis (RANTES = MCP-3 >> MCP-1 > MIP-1 alpha), histamine release (MCP-1 = MCP-3 >> RANTES > MIP-1 alpha), and leukotriene C4 formation, after IL-3 pretreatment (MCP-1 = MCP-3 >> RANTES > MIP-1 alpha). Thus, MCP-3 was as effective as MCP-1 as an inducer of mediator release, and as effective as RANTES as a stimulus of basophil migration. In contrast to MCP-1, MCP-3 was also a stimulus for eosinophils, and induced [Ca2+]i changes and chemotaxis as effectively as RANTES, which is the most potent chemotactic cytokine for these cells. Desensitization of the transient changes in [Ca2+]i was used to assess receptor usage. In basophils, stimulation with MCP-3 prevented responsiveness to MCP-1 and RANTES, but not to MIP-1 alpha. No single CC chemokine (except for MCP-3 itself) affected the response to MCP-3, however, which was prevented only when the cells were prestimulated with both MCP-1 and RANTES. In eosinophils, by contrast, cross-desensitization between RANTES and MCP-3 was obtained. RANTES and to a lesser extent MCP-3 also desensitized eosinophils toward MIP-1 alpha. The desensitization data suggest the existence of three chemokine receptors: (a) a MCP-1 receptor expressed on basophils but not eosinophils that is activated by MCP-1 and MCP-3; (b) a RANTES receptor in basophils and eosinophils that is activated by RANTES and MCP-3; and (c) a MIP-1 alpha receptor that is activated by MIP-1 alpha, RANTES and, more weakly, by MCP-3. This study shows that MCP-3 combines the properties of RANTES, a powerful chemoattractant, and MCP-1, a highly effective stimulus of mediator release, and thus has a particularly broad range of activities toward both human basophil and eosinophil leukocytes.
C-C趋化因子构成了一类新型细胞因子,可吸引并激活单核细胞、淋巴细胞以及嗜碱性粒细胞和嗜酸性粒细胞,具有不同的靶细胞谱,并且被认为参与了不同类型炎症的调节。研究了最近鉴定出的单核细胞趋化蛋白3(MCP-3)对人嗜碱性粒细胞和嗜酸性粒细胞功能的作用,并与其他C-C趋化因子进行了比较。在嗜碱性粒细胞中,MCP-3、MCP-1、RANTES和巨噬细胞炎性蛋白(MIP)-1α均诱导胞质游离钙浓度([Ca2+]i)变化,并以不同的效力诱导趋化性(RANTES = MCP-3 >> MCP-1 > MIP-1α)、组胺释放(MCP-1 = MCP-3 >> RANTES > MIP-1α)以及白三烯C4形成,在白细胞介素-3预处理后(MCP-1 = MCP-3 >> RANTES > MIP-1α)。因此,MCP-3作为介质释放诱导剂与MCP-1一样有效,作为嗜碱性粒细胞迁移刺激剂与RANTES一样有效。与MCP-1不同,MCP-3也是嗜酸性粒细胞的刺激剂,并且诱导[Ca2+]i变化和趋化性的效力与RANTES一样,RANTES是这些细胞最有效的趋化细胞因子。利用[Ca2+]i的瞬时变化脱敏来评估受体的使用情况。在嗜碱性粒细胞中,用MCP-3刺激可阻止对MCP-1和RANTES的反应,但不阻止对MIP-1α的反应。然而,没有单一的C-C趋化因子(除了MCP-3本身)影响对MCP-3的反应,只有当细胞先用MCP-1和RANTES预刺激时,这种反应才会被阻止。相比之下,在嗜酸性粒细胞中,获得了RANTES和MCP-3之间的交叉脱敏。RANTES以及程度较轻的MCP-3也使嗜酸性粒细胞对MIP-1α脱敏。脱敏数据表明存在三种趋化因子受体:(a)一种在嗜碱性粒细胞而非嗜酸性粒细胞上表达的MCP-1受体,可被MCP-1和MCP-3激活;(b)嗜碱性粒细胞和嗜酸性粒细胞中的一种RANTES受体,可被RANTES和MCP-3激活;(c)一种MIP-1α受体,可被MIP-1α、RANTES以及更弱程度地被MCP-3激活。这项研究表明,MCP-3兼具强大趋化剂RANTES和高效介质释放刺激剂MCP-1的特性,因此对人嗜碱性粒细胞和嗜酸性粒细胞具有特别广泛的活性。